Age at menarche and age at natural menopause are associated with causes of substantial morbidity and mortality such as breast cancer and cardiovascular disease. We conducted a joint analysis of two genome-wide association studies of these two traits in a total of 17,438 women from the Nurses' Health Study (NHS, N ¼ 2,287) and the Women's Genome Health Study (WGHS, N ¼ 15,151). For age at menarche, we identified ten associated SNPs (P ¼ 1 Â 10 À7 -3 Â 10 À13 ) clustered at 6q21 (in or near the gene LIN28B) and 9q31.2 (in an intergenic region). For age at natural menopause, we identified 13 associated SNPs (P ¼ 1 Â 10 À7 -1 Â 10 À21 ) clustered at 20p12.3 (in the gene MCM8), 19q13.42 (in or near the gene BRSK1), 5q35.2 (in or near genes UIMC1 and HK3) and 6p24.2 (in the gene SYCP2L). These newly identified loci might expand understanding of the biological pathways regulating these two traits.
Age at menarche and age at natural menopause have important implications for the health of pre-and postmenopausal women. They mark the beginning and the end of the normal reproductive life, and early menarche and later menopause are well-established risk factors for breast cancer 1 and endometrial cancer 2 . On the other hand, late menarche and early menopause increase risk of osteoporosis 3 and cardiovascular disease 4 . Early natural menopause also implies a reduced span of fertility 5 . Twin and family studies have suggested high heritability for age at menarche (53-74%) 6, 7 and age at natural menopause (49-87%) [8] [9] [10] . However, these estimates need to be viewed with caution as some studies have small sample sizes, and distinguishing between shared environment and true heritability is difficult for such environmentally influenced phenotypes. No correlation has been observed between the two traits, suggesting that they might be regulated differently 8 . Candidate gene association studies, focusing on the genes involved in steroid-hormone biosynthesis and metabolism pathways, have not yielded findings that have been consistently validated 11 . Recently, genome-wide linkage scans using microsatellite markers have identified chromosomal regions that might harbor genes for menarche [12] [13] [14] [15] and natural menopause 16, 17 , but no genes have been identified.
To identify common genetic variants associated with normal variation in age at menarche and age at natural menopause, we carried out a joint analysis of two genome-wide association (GWA) studies of these two traits in a total sample of 17,438 women from two prospective cohort studies, the Nurses' Health Study (NHS, N ¼ 2,287) and the Women's Genome Health Study (WGHS, N ¼ 15,151). The NHS sample consists of 1,145 women with postmenopausal invasive breast cancer and 1,142 matched controls. We evaluated 317,759 common SNPs (minor allele frequency (MAF) 4 1%) across the two studies. The means and s.d. of these two traits were similar between the NHS and the WGHS ( Supplementary Table 1 online). The mean age at menarche for the combined 17,406 women was 12.4 years (s.d. ¼ 1.43 years), whereas the mean age at natural menopause for the combined 9,112 women was 50.6 years (s.d. ¼ 3.58 years).
The distributions of the P values for the association tests across the SNPs tested showed little evidence of overall systematic bias or heterogeneity for age at menarche (genomic inflation factor for the combined analysis l ¼ 1.074; Supplementary Figs. 1a and 2a online) or age at natural menopause (l ¼ 1.026; Supplementary Figs. 1b and 2b). The excess of low P values was consistent with the presence of true associations for each phenotype. In the joint analysis of the two GWA studies, 10 and 13 SNPs reached genome-wide significance (P o 1 Â 10 À7 ) for age at menarche ( Fig. 1a ) and age at natural menopause ( Fig. 1b) , respectively. Detailed results for these candidate SNPs are listed in Table 1 . Although most of the SNPs associated with age at menarche showed no evidence of heterogeneity in effect estimates between the two studies, the effect estimates for two SNPs at 6q21 (rs314263 and rs369065) were significantly different (P for heterogeneity ¼ 0.0037 and 0.0078, respectively). However, other genomewide significant SNPs in this region (rs314277, rs314262, rs4946651 and rs314280) did not show evidence of statistical heterogeneity. Similarly, although one of the SNPs for age at natural menopause at 19q13.42 (rs1551562) showed some statistical evidence of heterogeneity (P for heterogeneity ¼ 0.04), five other genome-wide significant SNPs in this region (rs12611091, rs1172822, rs2384687, rs897798 and rs7246479) did not. We observed one SNP at 6q22.31 (rs12665088) that reached genome-wide significance for age at menarche in the NHS (major/minor allele ¼ G/A, beta ¼ À0.23, s.e. ¼ 0.043, P ¼ 5.0 Â 10 À8 ) but not in the joint analysis (P ¼ 2.1 Â 10 À3 ), and one SNP at 16p13.13 (rs10852344) that reached genomewide significance for age at natural menopause in the WGHS (major/ minor allele ¼ T/C, beta ¼ 0.34, s.e. ¼ 0.059, P ¼ 9.6 Â 10 À9 ) but not in the joint analysis (P ¼ 4.9 Â 10 À6 ). For each SNP that was genomewide significant in the combined analysis, the differences in age at menarche across genotype are generally much smaller than that of age at natural menopause (Supplementary Table 2 online), consistent with the narrower s.d. in age at menarche.
The ten genome-wide significant SNPs for age at menarche are clustered into two regions: six SNPs are at 6q21 ( Fig. 2a) ; the other four are at 9q31.2 (Fig. 2b) . In the 6q21 region, out of the four SNPs that are upstream of the LIN28B gene, three SNPs (rs4946651, rs314262 and rs314280) are in high linkage disequilibrium (LD) (pairwise r 2 4 0.95; Supplementary Table 3 online); the other two SNPs (rs314277 and rs369065) are in intron 2 of the LIN28B gene. Three SNPs (rs7028916, rs4452860, rs12684013) in the 9q31.2 intergenic region are in high LD (pairwise r 2 4 0.90; Supplementary  Table 3 ). After adjustment for the most significant SNPs in each region (rs314263, rs314277, rs7861820), none of the remaining genome-wide significant SNPs was significantly associated with age at menarche (all had P 4 0.05). Together, these three most significant SNPs from the two independent regions explained 0.60% of variation in age at menarche in the combined sample.
The 13 genome-wide significant SNPs for age at natural menopause are located in four different genomic regions: 5q32.2, 6p24.2, 19q13.42 and 20p12.3. In the 5q32.2 region, the three most significant SNPs (rs7718874, rs365132 and rs402511) are in perfect LD (each pairwise r 2 ¼ 1) ( Fig. 2c and Supplementary Table 3 ). Another SNP at 5q32.2, rs691141, is in relatively high LD with each of these SNPs (pairwise r 2 ¼ 0.83). We note that rs365132 is a synonymous SNP in exon 9 of the UIMC1 gene; the other genome-wide significant SNPs are distributed throughout the introns and flanking regions of UIMC1 and HK3. In the 6p24.2 region, rs2153157 is in intron 4 of the SYCP2L gene ( Fig. 2d ). Six SNPs in the 19q13.42 region are either in or downstream of the BRSK1 gene ( Fig. 2e) . The two most significant SNPs (rs1172822, rs2384687) in this region are in high LD (r 2 ¼ 0.81; Supplementary Table 3 ) as are two other SNPs with genome-wide significance (rs897798 and rs7246479, r 2 ¼ 0.82). At 20p12.3, rs16991615 had the smallest P value (1.2 Â 10 À21 ) in the combined analysis for age at natural menopause ( Fig. 2f ) and it is a nonsynonymous SNP in exon 9 of MCM8. After adjustment for one significant SNP in each region (rs7718874, rs2153157, rs1172822 and rs16991615), none of the remaining genome-wide significant SNPs was significantly associated with age at natural menopause (all had P 4 0.05). Together, these four significant SNPs from the four independent regions explained 2.69% of variation in age at natural menopause in the combined sample.
SNPs in the HapMap database with a pairwise correlation above 0.80 with the identified genome-wide significant SNPs in each region are listed in Supplementary Table 4 online.
In our results, the loci identified for age at menarche are different from those for age at natural menopause. Even at the nominal significance level (P o 0.05), none of the genome-wide significant SNPs for age at menarche was associated with age at natural menopause and vice versa. This is consistent with previous studies 8, 18 , suggesting that these traits might be regulated differently. We also observed fewer loci associated with age at menarche despite a larger sample size, which might be related to the fact that age at menarche had a more restricted age range (s.d. ¼ 1.43 years) compared to age at natural menopause (s.d. ¼ 3.58 years), and rounding reported age to the nearest year might increase the relative impact of measurement error and attenuate associations with age at menarche more than with age at natural menopause. Of note, none of the identified loci in this study contained previously reported candidate genes. We also did not observe any overlap between previously reported linkage peaks (lod 4 1.5) [12] [13] [14] [15] [16] [17] and the loci we identified.
This study reports novel findings for women of European ancestry recruited using similar techniques in the NHS and the WGHS. We chose to combine evidence for association to optimize power and calculate a summary estimate across the two studies despite the differences in the sample sizes 19 , as we observed no evidence of systematic heterogeneity in genetic association with either trait. For age at natural menopause, three of the four chromosomal regions that were genome-wide significant (P o 1.0 Â 10 À7 ) in the WGHS alone contained SNPs that had P o 0.05 in the NHS. Direction and magnitude of the observed associations were also consistent between the two studies across all four regions. This result constitutes independent replication in the NHS of the findings in the WGHS for at least three of the four regions. For age at menarche, although none of the SNPs that reached genome-wide significance in the WGHS analysis was independently significant at the 0.05 level in the NHS, in several instances the regression coefficients were very similar in magnitude and direction. There was no statistically significant evidence of heterogeneity for eight of the ten SNPs; for the other two SNPs, nearby SNPs in the region showed no significant heterogeneity. The reason we did not observe statistical significance in the NHS might be related to the modest absolute effects observed combined with the smaller sample size and the greater impact of SNP genome coordinate 8 measurement error on the analysis of age at menarche (see above). We cannot rule out the possibility that underlying differences in the two cohorts contribute to the observed discrepancy. Our estimates of magnitude of association need to be confirmed in additional studies, as they might be overestimated due to the 'winner's curse'; on the other hand, it is probable the SNPs detected in this study are not the causal loci, but are in LD with the causal variants that might have stronger associations. Fine-mapping of the regions will be needed to pinpoint the variants that will be nominated for subsequent studies designed to understand the biological basis of the observed associations. The ages at menarche and ages at natural menopause for women in these studies are comparable to those of the US general population, suggesting that findings from this study might be generalizable to women of European ancestry in the US population.
For age at menarche, the most significant association is in a region that contains the LIN28B gene, which encodes a developmentally regulated RNA-binding protein. This gene is highly expressed in most human hepatocellular carcinomas and embryonic stem cells. It functions as a negative regulator of microRNA (miRNA) by selectively blocking the processing of pri-let-7g miRNAs, and might have a critical role in stem cell fate determination and tumorigenesis 20 .
Several genes are present in the chromosomal regions identified for age at natural menopause. The MCM8 gene encodes a highly conserved mini-chromosome maintenance protein that is essential for genome replication 21 . The significant SNP (rs16991615) leads to an amino acid change from glutamic acid (Glu) to lysine (Lys) that might alter protein function. BRSK1 (also known as SAD1) is highly expressed in human brain at the presynaptic structure of neurons, and mutation or overexpression of the BRSK1 gene mislocates vesicles at the axonal terminals and thus affects vesicle transport and release at the axon terminals 22, 23 . It is possible that BRSK1 gene might affect the secretion of gonadotropin-releasing hormone (GnRH) from the hypothalamus through this mechanism, and thus disturb the control of the hypothalamic-pituitary-ovary axis on menstrual cycles and influence onset of the natural menopause. The UIMC1 (also known as RAP80) gene is expressed in the ovary and the hypothalamuspituitary-adrenal axis and can act as a transcriptional repressor. It has recently been identified to be in a complex with BRCA1, and is required for the localization of BRCA1 to DNA damage foci 24 . The HK3 gene is involved in carbohydrate metabolism and overexpressed in malignant follicular thyroid nodules 25 . Mouse SYCP2L is required for synaptonemal complex assembly and chromosomal synapsis during male meiosis. SYCP2L knockout mice show sterility in male mice and subfertility with sharply reduced litter size in female mice 26 .
In summary, we identified two and four loci that have not been reported previously to be associated with age at menarche and age at natural menopause, respectively. At these newly identified 13 20 loci fine mapping or sequencing might lead to identification of the causal variants, and thus expand our knowledge of the underlying physiology and biological regulation of these traits. Insights into the genetic factors influencing the timing of menarche and natural menopause might shed light on normal reproductive function and the prevention of the diseases associated with these two traits. 16; 17 or older.'' We excluded women whose age at menarche was reported as 18 years or greater in the NHS from the analysis (N ¼ 2), as these women were more likely to have a pathological cause outside the spectrum of normal variation. Age at natural menopause is defined as the age when menstrual periods ceased permanently and naturally (in years). Questions regarding menopause status were asked in baseline and subsequent questionnaires. The questions were: ''Have your menstrual periods ceased permanently?'' If yes, ''At what age did your natural periods cease?'' and ''For what reason did your periods cease?'' Response categories were ''Surgical; Radiation or Chemotherapy; Natural.'' Age at natural menopause was assessed in the baseline questionnaire for postmenopausal women at baseline, and updated in subsequent questionnaires for premenopausal women at baseline. By the time we conducted this study, all women in the NHS and the WGHS had passed through menopause and age at menopause was recorded, either at baseline, or on subsequent questionnaires. We used this most updated information for age at natural menopause in the analysis. Women who had radiation or chemotherapy or surgically induced menopause were excluded from the current study. We also excluded women who reported ages at menopause younger than 40 years or older than 60 years from the analysis, as these extremes might reflect underlying pathologies.
METHODS
Age at menarche and age at natural menopause are associated with breast cancer and other endpoints in both the NHS and the WHS with magnitudes and directions of association that are consistent with other published studies, attesting to the validity of the measurements. Further discussions about the validity of the measurement of age at menarche and age at natural menopause are provided in the Supplementary Methods. Genotyping. Genotyping in the NHS used the Illumina Infinium Sentrix HumanHap550 chip. Detailed methods related to the genotyping have been published previously 27 . Genotyping in the WGHS used either the Illumina HumanHap300 Duo-Plus chip or the combination of the HumanHap300 Duo and I-Select chips 28 . In the present analysis, the 317,759 SNPs shared between the NHS and the WGHS samples were almost entirely from the HumanHap300 panel.
Statistical analysis. In each of the NHS and the WGHS GWA studies separately, we carried out linear regression to analyze the association between each of the SNPs (coded as counts of minor alleles) and age at menarche or age at natural menopause as continuous variables using PLINK software 29 . SNPs with low MAF (o1%) in either the NHS or the WGHS samples were excluded from analysis. To control for potential confounding by population stratification, we adjusted for the top principal components of genetic variation chosen for each study after excluding any admixed individuals clearly not of European ancestry (see Supplementary Methods) . In the NHS analysis, controlling for breast cancer case-control status made no material difference to the GWA results. To combine evidence for association with age at menarche or age at natural menopause and calculate a summary effect size across the NHS and the WGHS, we used fixed-effect joint analysis; and heterogeneity in effect size across two studies was assessed using the Q-test 30 .
To estimate the proportion of variation in age at menarche and age at natural menopause that can be explained by the identified genome-wide significant SNPs, we pooled the original genotype and phenotype data from the NHS and the WGHS for the 23 genome-wide significant SNPs. After first adjusting the age at menarche or age at natural menopause for principal components of population substructure within each study separately, we performed a forward/backward stepwise selection of candidate SNPs with the BIC criteria in regression models that also included a study variable to select a minimal set of nonredundant SNPs for each phenotype. The proportion of variation explained (R 2 ) in the combined phenotype was calculated by comparing the model containing the final selected SNPs and a study variable to the model containing a study variable alone.
Statistical power. Assuming a correlation (r 2 ) between at least one tested SNP and any causal SNP is 0.80, our study has 80% power at a genome-wide significance level (P o 1 Â 10 À7 ) to detect any causal SNP accounting for 0.27% of phenotypic variation in observed age at menarche, and 0.52% of phenotypic variation in observed age at natural menopause.
Note: Supplementary information is available on the Nature Genetics website.
